A Phase 3 interventional study of Sub-Retinal Administration of OCU400-301 in Retinitis Pigmentosa, sponsored by Ocugen. Active, not recruiting at 17 sites in 2 countries. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Ocugen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 43 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 7th largest by enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2024, is one of 8 in phase 3, reaches primary completion later than 14 of the 41 other live ones, and was the 106th registered.
281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.
Browse Retinitis Pigmentosa studies →20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:
Nacuity Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Sumitomo Pharma America, Inc. · Sites in United States
Ages 18+
Octant, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Retinitis Pigmentosa studies recruiting now, 38 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 11 take healthy volunteers.
This study: 3 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 38 · Phase 3 11
First in 1993; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 27 across 180 interventional studies indexed under Retinitis Pigmentosa.
Median enrollment 21 across the 78 interventional studies, 73 across the 38 observational. Of the 70 that completed or were terminated, 30 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 119 have an industry lead sponsor. The 10 most frequent:
Ocugen is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Ocugen has 3 studies filed under Retinitis Pigmentosa — fewer than ten, so there is no comparison to draw.
11 of the studies in Retinitis Pigmentosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06388200Phase 3OcugenA Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | 2027-02-12 |
| NCT06912633jCyte, IncSafety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) | 2026-12 |
| NCT02086890Nova Southeastern UniversityElectro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa | 2026-12 |
| NCT04278131Bionic Sight LLCBS01 in Patients With Retinitis Pigmentosa | 2026-12-30 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
Add all 11 to your calendar (.ics) → With an account.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP.
This is a multicenter, assessor blinded and randomized study which will enroll 140 subjects. Study has completed enrollment of all 140 subjects.
A total of one hundred and forty (140) RP participants will be enrolled in this study into RHO arm or Gene agnostic arm. RHO arm will only enroll participants with confirmed genetic diagnosis of mutation in RHO gene; whereas Gene Agnostic arm will enroll RP Participants based on clinical diagnosis of RP and a confirmed genetic diagnosis with a gene associated with RP.
Subjects in each arm will be randomized into treatment and control groups with a 2:1 ratio. Subjects in the treatment group will receive a sequential, bilateral sub-retinal injection of OCU400 if both eyes meet inclusion criteria. Control or untreated group subjects will receive OCU400 subretinal injection after completion of 12-month follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive a sub-retinal injection of OCU400-301 modifier gene therapy product with a concentration of 2.5 x 10\^10 vg/eye
Genetic: Sub-Retinal Administration of OCU400-301
Subjects will receive a sub-retinal injection of OCU400-301 modifier gene therapy product with a concentration of 2.5 x 10\^10 vg/eye
Genetic: Sub-Retinal Administration of OCU400-301
Will not receive any active study intervention
Will not receive any active study intervention
Sub-Retinal Administration of OCU400-301
Change in functional vision from baseline to week 52 in pooled analysis when study eyes in treatment group were compared to study eyes in untreated control
Change in functional vision from baseline to week 52 in pooled analysis from retinitis pigmentosa subjects when study eyes in treatment group were compared to study eyes in untreated control, as measured by the ability of a study participant to navigate through a maze in Luminance Dependent Navigation Assessment (LDNA)
Time frame: 52 weeks
Change in functional vision from baseline to week 52 in all the treated eyes from RP subjects (study eyes + fellow treated eyes) when compared to all the eyes (study eyes and fellow eyes) in untreated control group
Change in functional vision from baseline to week 52 in all the treated eyes from RP subjects (study eyes + fellow treated eyes) when compared to all the eyes (study eyes and fellow eyes) in untreated control group, as measured by the ability of a study participant to navigate through a maze in Luminance Dependent Navigation Assessment (LDNA).
Time frame: 52 weeks
Change from Baseline in visual function in patients with retinitis pigmentosa when treatment group were compared to untreated controls
Change from Baseline in visual function in patients with retinitis pigmentosa when treatment group were compared to untreated controls in all RP subjects, as assessed by binocular low luminance visual acuity when using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart letter score at Week 52.
Time frame: 52 weeks
Change from baseline in LDNA Lux-level results in treated subjects when compared to the untreated controls
Change from baseline in LDNA Lux-level results in all RP subjects in treated subjects when compared to the untreated controls at weeks 12, 24, 36, and 52
Time frame: 52 weeks
Number of participants with change in visual function in Gene Agnostic Arm as assessed by LLVA letter scores
Change in LLVA letter scores in Gene Agnostic Arm subjects will be compared to controls
Time frame: 52 weeks
Change from baseline in Patients Global Impression of Change (PGIC) score
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Change from baseline in Patients Global Impression of Change (PGIC) score.
Time frame: 52 weeks
Change from baseline in Best corrected visual acuity (BCVA) measured by ETDRS
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Change from baseline in Best corrected visual acuity (BCVA) measured by ETDRS.
Time frame: 52 weeks
Improvement in Low luminance deficit (LLD) from baseline measured by ETDRS
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Improvement in Low luminance deficit (LLD) from baseline measured by ETDRS.
Time frame: 52 weeks
Improvement in mean retinal sensitivity from baseline as measured by static perimetry in the 30-degree
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Improvement in mean retinal sensitivity from baseline as measured by static perimetry in the 30-degree.
Time frame: 52 weeks
Change from baseline in hyperfluorescent ring as measured by Wide field-FAF
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Change from baseline in hyperfluorescent ring as measured by Wide field-FAF.
Time frame: 52 weeks
Change from baseline in area of RP atrophy in macular region as measured by Wide field-FAF
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Change from baseline in area of RP atrophy in macular region as measured by Wide field-FAF.
Time frame: 52 weeks
Change from baseline in hypo autofluorescence assessments in peripheral retina as measured by Wide field-FAF
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Change from baseline in hypo autofluorescence assessments in peripheral retina as measured by Wide field-FAF.
Time frame: 52 weeks
Change from baseline in hyper autofluorescence assessments in peripheral retina as measured by Wide field-FAF
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by change from baseline in hyper autofluorescence assessments in peripheral retina as measured by Wide field-FAF.
Time frame: 52 weeks
Changes in the Ellipsoid zone area from baseline as measured by SD-OCT
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by changes in Ellipsoid zone area from baseline as measured by SD-OCT.
Time frame: 52 weeks
Changes in the outer segment length from baseline as measured by SD-OCT
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by changes in the outer segment length as measured by SD-OCT.
Time frame: 52 weeks
Changes in the outer segment volume from baseline as measured by SD-OCT
Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by changes in the outer segment volume from baseline as measured by SD-OCT.
Time frame: 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Feb 2027, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ocugen